Clinical Trials Directory

Trials / Completed

CompletedNCT05832463

Effects of a Novel Supplement on Glycemic Variability Measured by Continuous Glucose Monitoring

Effects of a Novel Carbohydrate Blocking Supplement on Glycemic Variability as Measured by Continuous Glucose Monitoring

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
43 (actual)
Sponsor
dōTERRA International · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

This is a two-cohort, crossover pilot study to determine interstitial glucose levels coincident with the consumption of a novel carbohydrate blocking supplement.

Detailed description

This two-cohort study will evaluate a novel supplement developed for metabolic support using measures of glycemic variability, fasting glucose, and fasting insulin. In the first cohort, over the course of two weeks, these endpoints will be determined by continuous glucose monitoring (CGM) and blood/urine analyses in healthy adults using a carbohydrate blocking supplement (CBS). Following an interim analysis, the CBS will be evaluated for an additional two months in healthy volunteers using the same measures outlined above.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTCarbohydrate blocking supplement (CBS)The CBS is composed of a Hypromellose outer shell, and filled with mulberry leaf extract, berberine HCl, cinnamon bark powder, and cinnamon bark essential oil. Mulberry leaf extract (Reducose) - 250 mg Berberine HCl (97%)(Berberis aristata root extract)- 25 mg Organic cinnamon powder (Cinnamon (Cinnamomum loureirii) bark powder) - 20 mg Essential oil blend (Grapefruit (Citrus paradisii) peel oil, Lemon (Citrus limon) peel oil Peppermint (Mentha piperita) aerial (leaf/stem) oil), Ginger (Zingiber officinale) root oil, Cinnamon (Cinnamomum zeylanicum) bark oil) - 5 mg
DIETARY_SUPPLEMENTPlacebo capsuleThe placebo is composed of a Hypromellose outer shell filled with extra virgin olive oil.

Timeline

Start date
2021-05-14
Primary completion
2022-07-12
Completion
2022-07-15
First posted
2023-04-27
Last updated
2023-04-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05832463. Inclusion in this directory is not an endorsement.